Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deanna Armstrong

Plastic Surgery Elkhorn, NE Medical Doctor

NPI 1700803327 CMS profile 213647

717 N 190Th Plz Ste 2200, Elkhorn, NE 68022

Open in the dashboard

General payments

$5,499

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deanna Armstrong of Elkhorn, NE is reported in the CMS Open Payments database as having received $5,499 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $259 6
2024 General $1,746 17
2023 General $588 14
2022 General $849 15
2021 General $1,098 9
2020 General $255 4
2019 General $704 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deanna Armstrong
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Deanna Armstrong were reported at $259. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Deanna Armstrong Plastic Surgery median Middle half National median
2019 $704 $371 $122–$1,483 $163
2020 $255 $158 $52–$438 $114
2021 $1,098 $249 $87–$752 $132
2022 $849 $274 $102–$793 $149
2023 $588 $299 $113–$891 $160
2024 $1,746 $361 $124–$1,062 $164
2025 $259 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,913 16 payments
  2. Allergan Inc. $1,834 27 payments
  3. Baxter Healthcare $515 13 payments
  4. Smith+Nephew, Inc. $443 8 payments
  5. Sientra, Inc. $181 1 payment
  6. KCI USA, Inc $151 2 payments
  7. Avita Medical Americas, LLC $100 2 payments
  8. Integra LifeSciences Corporation $97 4 payments
  9. Regeneron Healthcare Solutions, Inc. $65 1 payment
  10. Solventum Corporation $34 2 payments
  11. Other $166 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,775 80 payments
  2. Travel and Lodging $1,724 4 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $3,242 19 payments
  2. REVOLVE $2,459 14 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $2,150 17 payments
  4. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $1,458 6 payments
  5. NATRELLE $344 9 payments
  6. ALLODERM $242 9 payments
  7. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $181 1 payment
  8. ARTISS Surgical Care $165 6 payments
  9. PICO $152 2 payments
  10. ARTISS Surgical Care $141 5 payments
  11. Other $2,239 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

164

Median for General Surgery: 59

Drug cost

$807

Median for General Surgery: $393

Branded share of claims

7.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 16 $263
Cephalexin Generic 49 $255
Oxycodone Hcl Generic 36 $128
Promethazine Hcl Generic 32 $109
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $41
Gabapentin Generic 19 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$48,070

Medicare's payments for the services billed

Medicare patients

61

Average age 71

Services billed

166

49 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 56%
Cancer 49%
Diabetes 38%
Chronic kidney disease 33%
Depression 28%
Heart failure 23%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record